Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Biomarkers for Parkinson’s Disease with Reflex Tears Stratified by Disease Duration
Movement Disorders
S16 - Movement Disorders: PD Biomarkers and Clinical Trials (3:42 PM-3:54 PM)
002

We have previously shown that oligomeric alpha synuclein is significantly elevated in both basal tears[1] (anesthetized Schirmer’s test) and reflex tears [2](unanesthetized Schirmer’s test) versus HC. Our patient sample was homogeneous related to disease duration. We have designed this study to evaluate the efficacy of collecting reflex tears to evaluate differentiation of PD progression versus HC.  

To evaluate whether the protein composition of reflex tears differs in Parkinson’s disease (PD) patients stratified by disease duration versus Healthy controls (HC)

Reflex tears were collected from 77 male and female early (disease duration 0-4 years), 43 intermediate (5-8 years), and 50 late (greater than 9 years) PD patients and 67 male and female HC using an unanesthetized Schirmer’s test. Samples were pooled from both eyes for analysis of oligomeric alpha-synuclein. Values were measured by ELISA and normalized to protein content of the sample.

Oligomeric alpha-synuclein was significantly increased by 5.4-fold in tears of early PD patients (4.28 ± 0.75 ng/mg tear protein, p-value<0.001), 4.0-fold in tears of intermediate PD (3.23 ± 0.54 ng/mg tear protein, p-value<0.001) and 3.1 fold in tears of late PD (2.44 ± 0.40 ng/mg tear protein, p-value<0.001) relative to HC (0.80 ± 0.24 ng/mg tear protein). No significant sex differences were present.

Oligomeric synuclein levels in tear fluid does not enable discrimination between various stages of PD patients based on disease duration compared to HC. The current study is conducted in an independent cohort compared to our previous studies and the results  1) validate previous findings that oligomeric alpha-synuclein levels are increased in reflex tears of PD patients compared to HC; and 2) suggest that elevations in oligomeric alpha-synuclein are  stable across patients with early stage, intermediate and late stage PD. This is the first presentation of tear fluid evaluation in PD patients stratified by disease duration.

Authors/Disclosures
Mark F. Lew, MD, FAAN (USC School of Medicine)
PRESENTER
Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus. Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for kyowa. Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for neurocrine. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RegenXBio. Dr. Lew has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine. Dr. Lew has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Kyowa. Dr. Lew has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for acorda. The institution of Dr. Lew has received research support from MJFF. Dr. Lew has received research support from NIH.
No disclosure on file
No disclosure on file
Danielle Feigenbaum, MD (Usc) Dr. Feigenbaum has nothing to disclose.
Amir Besharat, DO (Swedish Neurosciences Institute) Dr. Besharat has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Wendy Mack No disclosure on file
No disclosure on file
No disclosure on file